IL102542A - דיבנז ]b,f[ ]1,4[ אוקסאזפין -h)0111(-אונים ותכשירי רוקחות המכילים אותם - Google Patents

דיבנז ]b,f[ ]1,4[ אוקסאזפין -h)0111(-אונים ותכשירי רוקחות המכילים אותם

Info

Publication number
IL102542A
IL102542A IL10254292A IL10254292A IL102542A IL 102542 A IL102542 A IL 102542A IL 10254292 A IL10254292 A IL 10254292A IL 10254292 A IL10254292 A IL 10254292A IL 102542 A IL102542 A IL 102542A
Authority
IL
Israel
Prior art keywords
compound
dibenz
chloro
ethyl
oxazepin
Prior art date
Application number
IL10254292A
Other languages
English (en)
Other versions
IL102542A0 (en
Inventor
Ivo Monkovic
Lotte Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL102542A0 publication Critical patent/IL102542A0/xx
Publication of IL102542A publication Critical patent/IL102542A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
IL10254292A 1991-08-26 1992-07-17 דיבנז ]b,f[ ]1,4[ אוקסאזפין -h)0111(-אונים ותכשירי רוקחות המכילים אותם IL102542A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/749,741 US5173486A (en) 1991-08-26 1991-08-26 Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents

Publications (2)

Publication Number Publication Date
IL102542A0 IL102542A0 (en) 1993-01-14
IL102542A true IL102542A (he) 1995-12-31

Family

ID=25014983

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10254292A IL102542A (he) 1991-08-26 1992-07-17 דיבנז ]b,f[ ]1,4[ אוקסאזפין -h)0111(-אונים ותכשירי רוקחות המכילים אותם

Country Status (22)

Country Link
US (1) US5173486A (he)
EP (1) EP0529386B1 (he)
JP (1) JP3136427B2 (he)
KR (1) KR100204119B1 (he)
CN (1) CN1038749C (he)
AT (1) ATE149158T1 (he)
AU (1) AU642602B2 (he)
CA (1) CA2075861C (he)
DE (1) DE69217594T2 (he)
DK (1) DK0529386T3 (he)
ES (1) ES2097841T3 (he)
FI (1) FI112656B (he)
GR (1) GR3022698T3 (he)
HK (1) HK1005029A1 (he)
HU (1) HU214584B (he)
IL (1) IL102542A (he)
MX (1) MX9204791A (he)
NO (2) NO301586B1 (he)
PL (1) PL168707B1 (he)
RU (1) RU2086545C1 (he)
TW (1) TW213905B (he)
ZA (1) ZA925287B (he)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
DK2149372T3 (da) * 2008-07-31 2014-07-07 Universität Ulm Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer
CN104016937B (zh) * 2014-05-09 2016-12-07 中科院广州化学有限公司 一种n-芳基氧氮杂卓酮类化合物及其制备方法
US11649218B2 (en) 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546214A (en) * 1967-07-11 1970-12-08 Boehringer Sohn Ingelheim Amino-substituted dibenz(b,f)(1,4)oxazepin-11(10h)-ones

Also Published As

Publication number Publication date
HU214584B (hu) 1998-04-28
ES2097841T3 (es) 1997-04-16
CN1038749C (zh) 1998-06-17
KR100204119B1 (ko) 1999-06-15
ATE149158T1 (de) 1997-03-15
CA2075861C (en) 2003-08-05
HK1005029A1 (en) 1998-12-18
NO301586B1 (no) 1997-11-17
NO923049L (no) 1993-03-01
HUT63837A (en) 1993-10-28
DE69217594T2 (de) 1997-10-02
EP0529386B1 (en) 1997-02-26
PL295633A1 (en) 1993-03-08
KR930004281A (ko) 1993-03-22
DK0529386T3 (da) 1997-07-28
HU9202319D0 (en) 1992-10-28
US5173486A (en) 1992-12-22
TW213905B (he) 1993-10-01
CA2075861A1 (en) 1993-02-27
NO923049D0 (no) 1992-08-03
GR3022698T3 (en) 1997-05-31
AU642602B2 (en) 1993-10-21
RU2086545C1 (ru) 1997-08-10
NO972247D0 (no) 1997-05-16
JP3136427B2 (ja) 2001-02-19
FI923285A0 (fi) 1992-07-17
NO972247L (no) 1997-05-16
DE69217594D1 (de) 1997-04-03
JPH05194442A (ja) 1993-08-03
FI112656B (fi) 2003-12-31
PL168707B1 (pl) 1996-03-29
EP0529386A1 (en) 1993-03-03
ZA925287B (en) 1993-04-28
MX9204791A (es) 1993-01-01
CN1069731A (zh) 1993-03-10
FI923285A (fi) 1993-02-27
IL102542A0 (en) 1993-01-14
NO309603B1 (no) 2001-02-26
AU2074292A (en) 1993-03-04

Similar Documents

Publication Publication Date Title
KR102630069B1 (ko) 아폽토시스-유도제
CA2445395C (en) Heterocyclic compound and antitumor agent comprising the same as effective component
KR100563514B1 (ko) 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제
EP0243959B1 (en) Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
US5173486A (en) Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
US20050171101A1 (en) Phenanthridinones as parp inhibitors
US20060122229A1 (en) 4,5-diarylthiazole derivatives as cb-1 ligands
WO2007129111A1 (en) Diazepine derivatives as 5-ht2a antagonists
IL124337A (he) נגזרות פירידו-אוקסזין, תכשירי רוקחות המכילים אותן ושיטה להכנתן
AU2018353122B2 (en) Amine-substituted heterocyclic compounds as EHMT2 inhibitors, salts thereof, and methods of synthesis thereof
CA2074061A1 (en) Benzamide multidrug resistance reversing agents
AU7972698A (en) Alpha 1a adrenergic receptor antagonists
JPH0735373B2 (ja) カルボン酸アミド化合物
CA2171782A1 (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
WO2019149128A1 (zh) 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物
US4994569A (en) 5,6-dihydro-4H-1,3-oxa(or thia)zine derivatives, their preparation and compositions containing them
CN113929674B (zh) 含1,4-二氢喹唑啉结构的化合物及其制备方法与应用
KR19990035986A (ko) 심근 저혈 치료용 헤테로사이클릭 화합물
WO1994003439A1 (en) Antiproliferative tricyclic compounds
KR20240136406A (ko) 신규한 cdk9 억제제

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees